BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vaxil Reports Promising Results From Its Follow-Up Clinical Trial of ImMucin in Multiple Myeloma a Patients


6/18/2013 10:53:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ness Ziona, 18th June 2013. Vaxil Bio (TASE: VAXL) which is developing therapeutic vaccines to treat cancer and infectious diseases, reports promising results that were observed in its follow-up study VAXIL-002 on multiple myeloma patients. Four out of the five patients enrolled in the study are still in a remission from their illness and have been so for a period of between 12 and 26 months following completion of their treatment with ImMucin, the company's therapeutic vaccine. The fifth patient was in a period of remission of 13 months following completion of his treatment with ImMucin until the disease returned and he was taken out of the study. Monitoring of these patients is being carried out at Hadassah Medical Center, Jerusalem and the patients are not receiving any other treatments.

These results will be presented by Dr. Lior Carmon in the IATI-BIOMED conference which is taking place this week in Tel Aviv.

In April 2013, Vaxil reported on its success in meeting all the endpoints of the clinical trial VAXIL-001 on 15 patients with multiple myeloma (a bone marrow cancer). All the patients enrolled in this study were experiencing a gradual re-emergence of the disease after a period of remission that had been attained by an autologous stem cell transplantation. The results demonstrated a high safety profile for ImMucin. In addition, 100% of the patients demonstrated a strong immunological response to ImMucin. Furthermore, nine of the 15 patients demonstrated a clinical response. Of these, five patients ended the study in a state of Complete Response and a further four ended the study with Stable Disease, which required no further treatment.

Please view this animated film which explains how Vaxil's therapeutic vaccine ImMucin works http://www.youtube.com/watch?feature=player_embedded&v=XhEwj6Ue13s#!

About Vaxil

Vaxil is an Israeli clinical stage biotechnology company developing therapeutic vaccines to treat cancer and infectious diseases. The company's vaccines are based on its proprietary technology, VaxHit, which identifies vaccine candidates (Signal peptide domains) with the ability to create a specific, strong and promiscuous reaction in various immune system types (PAN-HLA). As opposed to traditional prophylactic vaccines which protect healthy people from disease, a therapeutic vaccine takes sick people and seeks to educate their immune system to identify and destroy cancer cells (or pathogens in the case of infectious diseases) in a safe, efficient and focused manner, typically with far fewer side effects than other cancer treatments. From the patient’s perspective a therapeutic vaccine is a drug.

Vaxil’s lead product, ImMucin, teaches the patient’s immune system to identify and destroy cells which display a specific domain from the cancer marker MUC1 (which appears on 90% of all cancers). In 2013, Vaxil completed a Phase I/II clinical study with ImMucin on multiple myeloma patients. The study succeeded in meeting all endpoints. Vaxil is currently planning a Phase II study using ImMucin in multiple myeloma and a further study in a solid tumor (e.g. lung or breast cancer.

Vaxil is also developing MTBuVax, a therapeutic vaccine for tuberculosis (“TB”). Globally, TB is one of the largest causes of mortality. Although most TB cases occur in developing countries, over the last few years, there has been an increase in incidence rates in the western world due to the low efficacy of the current TB vaccine (BCG), increased global travel movements, the mutation of the TB bacteria to new strains which are resistant to drug treatment and a strong link of TB with HIV infection. MTBuVax is in pre-clinical studies. Vaxil was founded in 2006 by Dr. Lior Carmon, an expert in cancer immunotherapy, who holds a PhD from the Weizmann Institute in tumor immunology, and Julian Levy, a seasoned biotechnology entrepreneur who holds an MA from Cambridge University in Law. The two have considerable experience founding and running bio-tech projects.

For further details please visit the company's website at www.vaxilbio.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES